Nurofen Plus Recalled; Sabotage Suspected - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Nurofen Plus Recalled; Sabotage Suspected


ePT--the Electronic Newsletter of Pharmaceutical Technology

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) issued several press releases Aug. 25–26, 2011, regarding the discovery of rogue medicines in packs of Reckitt Benckiser’s Nurofen Plus.

The most recent of the press releases announces that Reckitt Benckiser (UK) Ltd is to recall all remaining unexpired stock of Nurofen Plus tablets of any pack size as a precautionary measure. The discovery of AstraZeneca's anti-psychotic drug Seroquel XL in Nurofen Plus packs on Aug. 25, 2011 was followed by a pack containing Pfizer's Neurontin 100mg, used to treat epilepsy, being found in Northern Ireland on Aug. 26, 2011.

The MHRA advised the public in a previous press release to return any packs of Nurofen Plus pain relief tablets to any pharmacy. The release also indicated the differences between the blister packs and medicines contained within. Seroquel tablets are large and capsule shaped in gold and black packaging, Nurofen Plus blister packs are silver and black, and Neurontin tablets are white capsules printed with name of the drug. Ian Holloway from the MHRA's Defective Medicines Report Centre (DMRC) said, "People should check to see if they have any packets of Nurofen Plus. If you do, return them to your nearest pharmacy."

Reckitt Benckiser issued the recall on the Nurofen website and stated, "Sabotage is suspected and we are working with the police on a formal investigation to find the person or persons responsible. Distribution of Nurofen Plus has been halted at this time."

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here